(Total Views: 542)
Posted On: 04/12/2020 9:42:59 PM
Post# of 72447
Could Brilacidin be part of Janssen’s (aka Johnson & Johnson) compounds they are investigating or are the compounds in the description solely their compounds?
Could Brilacidin be part of Janssen’s (aka Johnson & Johnson) compounds they are investigating or are the compounds in the description solely their compounds?
“The Biomedical Advanced Research and Development Authority (BARDA), part of ASPR, will collaborate with Janssen to identify medicines that might be used safely and effectively to reduce the severity of illness and treat coronavirus infections. The company also will identify compounds that have antiviral activity against SARS-CoV-2 as an initial step in developing new treatments. Currently, there are no vaccines or therapeutics approved by the U.S. Food and Drug Administration (FDA) to treat or prevent novel coronavirus infections.
This library to be screened consists of approved therapeutics as well as investigational therapeutics that have completed some clinical trials so that basic safety and pharmacology data are available for these compounds. If screening is promising, candidates then could be considered for further development, including assessment in additional clinical studies.”
https://www.hhs.gov/about/news/2020/02/18/hhs...utics.html
Could Brilacidin be part of Janssen’s (aka Johnson & Johnson) compounds they are investigating or are the compounds in the description solely their compounds?
“The Biomedical Advanced Research and Development Authority (BARDA), part of ASPR, will collaborate with Janssen to identify medicines that might be used safely and effectively to reduce the severity of illness and treat coronavirus infections. The company also will identify compounds that have antiviral activity against SARS-CoV-2 as an initial step in developing new treatments. Currently, there are no vaccines or therapeutics approved by the U.S. Food and Drug Administration (FDA) to treat or prevent novel coronavirus infections.
This library to be screened consists of approved therapeutics as well as investigational therapeutics that have completed some clinical trials so that basic safety and pharmacology data are available for these compounds. If screening is promising, candidates then could be considered for further development, including assessment in additional clinical studies.”
https://www.hhs.gov/about/news/2020/02/18/hhs...utics.html
(3)
(1)
